…
Materialise NV provides additive manufacturing and medical software tools, and 3D printing services in the Americas, Europe, Africa, and the Asia-Pacific. The company operates through three segments: Materialise Software, Materialise Medical, and Materialise Manufacturing. The Materialise Software segment offers proprietary software through programs and platforms that enable and enhance the functionality of 3D printers, and printing operations. Its software interfaces between various types of 3D printers; and various software applications and capturing technologies, including computer-aided design/computer-aided manufacturing packages and 3D scanners; a MES, software providers. This segment serves 3D printing machine manufacturers; production companies and contract manufacturers in automotive, aerospace, consumer goods, and hearing aid industries; and 3D printing service bureaus through its sales force, website, and third-party distributors. The Materialise Medical segment provides medical software that allows medical-image based analysis, planning, and engineering, as well as patient-specific design and printing of surgical devices and implants. It serves medical device companies, hospitals, universities, research institutes, and industrial companies. The Materialise Manufacturing segment provides 3D printing services, design and engineering services, and rapid prototyping and additive manufacturing of production parts to customers serving the automotive, consumer goods industrial goods, semiconductor, art and architecture and aerospace markets. The company has collaboration agreements with Zimmer Biomet Holdings, Inc.; Encore Medical, L.P.; DePuy Synthes Companies of Johnson & Johnson; Limacorporate Spa; Mathys AG; Smith & Nephew Inc.; Corin Ltd; Medtronic Inc.; and Abbott Laboratories Inc. Materialise NV was incorporated in 1990 and is headquartered in Leuven, Belgium.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 7.00M | 14.14M | 6.63M | -1.18M | 13.74M |
| Minority interest | 0.00M | 0.03M | 0.03M | 0.03M | 0.01M |
| Net income | 7.41M | 13.44M | 6.72M | -2.15M | 13.15M |
| Selling general administrative | 85.51M | 39.60M | 79.81M | 35.14M | 32.60M |
| Selling and marketing expenses | 10.81M | 61.62M | 10.44M | 62.12M | 49.15M |
| Gross profit | 146.91M | 150.82M | 142.16M | 128.76M | 117.28M |
| Reconciled depreciation | 21.70M | 21.76M | 21.57M | 22.57M | 20.52M |
| Ebit | 4.94M | 9.43M | 11.89M | 3.24M | 17.84M |
| Ebitda | 25.79M | 31.24M | 33.02M | 25.81M | 38.35M |
| Depreciation and amortization | 20.85M | 21.81M | 21.13M | 22.57M | 20.52M |
| Operating income | 4.94M | 9.43M | 11.89M | 3.24M | 17.84M |
| Other operating expenses | 252.13M | 257.33M | 238.98M | 234.90M | 193.23M |
| Interest expense | 5.39M | 1.65M | 1.75M | 4.42M | 4.10M |
| Tax provision | -0.43M | 0.73M | 0.08M | 0.97M | 0.59M |
| Interest income | 2.84M | 4.25M | 3.48M | 6.11M | 5.62M |
| Net interest income | 0.78M | 2.60M | 2.36M | 1.69M | 1.52M |
| Income tax expense | -0.41M | 0.73M | 0.08M | 0.97M | 0.59M |
| Total revenue | 257.07M | 266.76M | 250.88M | 232.02M | 205.45M |
| Total operating expenses | 141.97M | 141.39M | 130.26M | 131.64M | 105.06M |
| Cost of revenue | 110.16M | 115.94M | 108.72M | 103.26M | 88.17M |
| Total other income expense net | 2.06M | 4.71M | -5.26M | -4.42M | -4.10M |
| Net income from continuing ops | 7.72M | 13.41M | 6.69M | -2.15M | 13.14M |
| Net income applicable to common shares | - | - | - | -2.12M | 13.15M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 420.47M | 396.34M | 396.96M | 411.26M | 413.41M |
| Intangible assets | 25.63M | 29.97M | 31.46M | 37.88M | 31.67M |
| Other current assets | 19.84M | 18.16M | 9.17M | 8.42M | 8.94M |
| Total liab | 165.09M | 147.84M | 160.17M | 182.33M | 180.83M |
| Total stockholder equity | 255.45M | 248.58M | 236.84M | 228.96M | 232.58M |
| Other current liab | 17.90M | 16.95M | 17.49M | 18.80M | 16.75M |
| Common stock | 4.49M | 4.49M | 4.49M | 4.49M | 4.47M |
| Capital stock | 4.49M | 4.49M | 4.49M | 4.49M | 4.49M |
| Retained earnings | 47.16M | 19.00M | -1.78M | -9.43M | -0.91M |
| Other liab | - | - | - | 15.20M | 11.49M |
| Good will | 43.14M | 43.39M | 43.19M | 44.16M | 18.73M |
| Other assets | - | - | - | 0.00M | 7.75M |
| Cash | 133.86M | 102.30M | 127.68M | 140.87M | 196.03M |
| Total current liabilities | 91.84M | 102.18M | 105.04M | 106.11M | 91.43M |
| Current deferred revenue | 43.50M | 46.00M | 40.82M | 41.72M | 33.31M |
| Net debt | -67.71M | -61.02M | -63.23M | -59.89M | -96.92M |
| Short term debt | 10.32M | 13.00M | 25.50M | 19.96M | 21.20M |
| Short long term debt | 7.76M | 10.38M | 22.87M | 17.06M | 17.85M |
| Short long term debt total | 66.15M | 41.28M | 64.45M | 80.98M | 99.11M |
| Other stockholder equity | 203.81M | 234.23M | 238.63M | 242.16M | 235.77M |
| Property plant equipment | - | - | - | 102.70M | 93.50M |
| Total current assets | 223.51M | 190.51M | 206.64M | 216.41M | 257.80M |
| Long term investments | 0.00M | 3.99M | 3.74M | 3.80M | 3.96M |
| Net tangible assets | - | - | - | 146.93M | 182.18M |
| Net receivables | 54.91M | 53.05M | 52.74M | 51.04M | 41.54M |
| Long term debt | 49.73M | 23.18M | 33.58M | 55.87M | 72.64M |
| Inventory | 14.90M | 16.99M | 17.05M | 16.08M | 11.29M |
| Accounts payable | 20.12M | 23.35M | 21.21M | 25.63M | 20.17M |
| Accumulated other comprehensive income | - | -9.08M | -7.35M | -8.27M | -6.75M |
| Non currrent assets other | 5.98M | 9.41M | 5.57M | 5.13M | 7.52M |
| Non current assets total | 196.96M | 205.82M | 190.32M | 194.85M | 155.60M |
| Capital lease obligations | 5.63M | 7.73M | 7.94M | 8.05M | 8.62M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -28.59M | -14.00M | -53.92M | -13.13M |
| Change to liabilities | - | - | - | 22.62M | 6.45M |
| Total cashflows from investing activities | -9.32M | -28.59M | - | -53.86M | -13.13M |
| Net borrowings | 20.88M | -26.39M | - | -21.09M | -18.05M |
| Total cash from financing activities | 18.00M | -27.64M | -20.20M | -24.87M | 71.16M |
| Net income | 7.41M | 13.41M | 6.58M | -2.15M | 13.14M |
| Change in cash | 43.70M | -25.27M | -12.79M | -55.16M | 84.49M |
| Begin period cash flow | 90.16M | 127.57M | 140.47M | 196.03M | 111.54M |
| End period cash flow | 133.86M | 102.30M | 127.68M | 140.87M | 196.03M |
| Total cash from operating activities | 22.68M | 31.46M | 18.03M | 24.71M | 25.84M |
| Issuance of capital stock | - | 0.00M | 0.02M | 0.02M | 88.12M |
| Depreciation | 20.85M | 21.76M | 21.13M | 22.57M | 20.52M |
| Other cashflows from investing activities | 5.93M | -1.27M | - | - | 0.00M |
| Dividends paid | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change to inventory | -0.87M | -0.37M | -0.79M | -5.01M | -1.42M |
| Change to account receivables | -2.57M | -1.04M | -3.27M | -6.33M | -10.92M |
| Other cashflows from financing activities | -5.01M | -1.25M | -0.34M | -1.47M | -2.42M |
| Change to netincome | - | - | - | 0.82M | -1.94M |
| Capital expenditures | 13.54M | 26.38M | 11.52M | 24.77M | 11.72M |
| Change in working capital | -8.49M | -1.42M | -12.32M | 3.44M | -5.89M |
| Stock based compensation | 0.27M | 0.28M | 0.04M | -0.14M | -1.04M |
| Other non cash items | 3.34M | -2.58M | 2.53M | 0.03M | -1.48M |
| Free cash flow | 9.14M | 5.08M | 6.51M | -0.06M | 14.12M |
Sector: Technology Industry: Software - Application
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MTLS Materialise NV |
-0.38 5.36% |
6.62 | 28.37 | 625.00 | 1.62 | 1.48 | 1.13 | 7.97 |
| SAP SAP SE ADR |
-0.29 0.12% |
233.81 | 28.16 | 22.42 | 6.52 | 4.85 | 5.60 | 16.61 |
| CRM Salesforce Inc |
-2.48 1.14% |
215.53 | 23.41 | 15.55 | 4.79 | 5.56 | 5.55 | 14.88 |
| SAPGF SAP SE |
0.50 0.21% |
234.50 | 76.28 | 22.88 | 5.61 | 3.84 | 5.59 | 26.18 |
| SHOP Shopify Inc |
-1.14 0.76% |
148.12 | 90.18 | 53.19 | 12.70 | 13.17 | 12.23 | 67.86 |
Materialise NV provides additive manufacturing and medical software tools, and 3D printing services in the Americas, Europe, Africa, and the Asia-Pacific. The company operates through three segments: Materialise Software, Materialise Medical, and Materialise Manufacturing. The Materialise Software segment offers proprietary software through programs and platforms that enable and enhance the functionality of 3D printers, and printing operations. Its software interfaces between various types of 3D printers; and various software applications and capturing technologies, including computer-aided design/computer-aided manufacturing packages and 3D scanners; a MES, software providers. This segment serves 3D printing machine manufacturers; production companies and contract manufacturers in automotive, aerospace, consumer goods, and hearing aid industries; and 3D printing service bureaus through its sales force, website, and third-party distributors. The Materialise Medical segment provides medical software that allows medical-image based analysis, planning, and engineering, as well as patient-specific design and printing of surgical devices and implants. It serves medical device companies, hospitals, universities, research institutes, and industrial companies. The Materialise Manufacturing segment provides 3D printing services, design and engineering services, and rapid prototyping and additive manufacturing of production parts to customers serving the automotive, consumer goods industrial goods, semiconductor, art and architecture and aerospace markets. The company has collaboration agreements with Zimmer Biomet Holdings, Inc.; Encore Medical, L.P.; DePuy Synthes Companies of Johnson & Johnson; Limacorporate Spa; Mathys AG; Smith & Nephew Inc.; Corin Ltd; Medtronic Inc.; and Abbott Laboratories Inc. Materialise NV was incorporated in 1990 and is headquartered in Leuven, Belgium.
| Name | Title | Year Born |
|---|---|---|
| Mr. Johan Pauwels | Exec. VP & COO | 1968 |
| Mr. Peter E. Leys | Exec. Chairman | 1965 |
| Mr. Wilfried Vancraen | Founder, CEO & Director | 1962 |
| Mr. Johan Albrecht | Exec. VP & CFO | 1963 |
| Mr. Bart Van der Schueren | Exec. VP & CTO | 1968 |
| Ms. Carla Van Steenbergen | VP, Chief Legal Officer, Compliance Officer & Sec. | 1976 |
| Ms. Conny Hooghe | VP of HR | 1966 |
| Ms. Hilde Ingelaere | Exec. VP of Medical & Director | 1963 |
| Mr. Filip Dehing | Chief Exec. Officer of RapidFit NV | 1971 |
| Ms. Brigitte de Vet-Veithen | Chief Executive Officer | 1972 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.